Burroughs Wellcome’s Flolan
Clinical study in patients with severe end-stage congestive heart failure discontinued due to higher rate of mortality in Flolan (epoprostenol) treated group compared to the standard therapy, firm reports June 21. In the trial of 450 patients, which began 18 months ago, quality of life and exercise tolerance also declined for the Flolan-treated group. The company said that the results in congestive heart failure do not affect the development of Flolan for primary pulmonary hypertension, an orphan indication for which Burroughs Wellcome is planning to file an NDA in 1993 ("The Pink Sheet" May 10, p. 14).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth